A four year old girl with systemic onset juvenile idiopathic arthritis (SOJIA) developed macrophage activation syndrome (MAS) shortly after starting methotrexate. We observed methotrexate is a likely trigger of MAS in SOJIA. Possibly, there are only two case reports suggesting methotrexate triggered MAS. We reviewed the literature for possible mechanisms.
Introduction
M acrophage activation syndrome (MAS) is a devastating complication of systemic onset juvenile idiopathic arthritis (SOJIA) with uncertain aetiopathopathogenesis. Ravelli et al 1 had suggested that methotrexate may be a triggering factor for MAS in SOJIA although Eraso et al 2 and others refuted their observations. Role of methotrexate in inducing MAS in SOJIA is contemplated in the case report.
The Case
A four year old girl admitted with fever for one year and evanescent rash with multiple joint pains for ten months. She was diagnosed as a case of SOJIA according to ILAR guideline 3 . Child was taking ibuprofen for one month before admission. Upon admission, we classifi ed her as "systemic arthritis with active arthritis'' according to American College of Rheumatology guidelines 4 and started methotrexate. The next day, she developed pruritus and highgrade, non-remittent fever, with abdominal pain and lethargy. Newonset lymphadenopathy and hepatosplenomegaly were observed and fresh tests revealed bicytopenia and low fi brinogen with elevated CRP, transaminases, INR, triglyceride and ferritin (Table1). She was diagnosed to have developed MAS and died four days later. 8 reported development of CD+ T-cell lymphoproliferative disorder with EBV genome in a RA patient, during methorexate therapy. Neurathet al 9 . observed that while methotrexate reduced interleukin and TNF production in synovial fl uid, the levels of these cytokines were unaff ected in peripheral blood. They also observed that TNF production was reduced from T-lymphocytes, but not from macrophages. Also at antirheumatoid doses, although methotrexate decreases pro-infl ammatory cytokines, but cell proliferation is negligibly aff ected. Infact, at anti-rheumatoid dose, the blood concentration of methotrexate is one-tenth its concentration in synovial fl uid 9 . Hence, its actions in the joints and in extra-articular tissues may be diff erent. We speculate that in few SOJIA patients, methotrexate may actually increase the cytotoxic T-lymphocytes in extraarticular regions, and initiate MAS.
Discussion
Halevey et al. 10 reported leucocytoclastic vasculitis in the small vessels of a Rheumatoid Arthritis (RA) patient treated with Methotrexate, which proves the potential ability of Methotrexate to induce autoimmune infl ammation in RA.
Methotrexate is an anti-folate drug. It is relevant that another anti-folate drug, sulphamethoxazoletrimethoprim, rarely causes DRESS (Drug rash with eosinophilia and systemic symptoms) 11 , which is an acute immune-mediated reaction causing macrophage and T-lymphocyte activation and cytokine release, reminiscent of drug-induced MAS.
Thus we feel that methotrexate is a possible cause of MAS in SOJIA.
Conclusion
This case report may open the debate whether methotrexate, a common drug, has this potentially lethal side eff ect in SOJIA. Paediatricians who are well informed of such possibility will have a higher index of suspicion about methotrexate during their daily practice. This will contribute to salvaging more patients as well as enrichment of the medical literature with more similar case reports.
